Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA To Join The 'Real World' Under PDUFA VI

Executive Summary

Under round six of the user fee agreement with industry, the FDA is pledging to explore the use of real-world evidence, strengthen the patient's voice in the drug review process and boost the agency's postmarketing surveillance abilities.


Related Content

PDUFA VI: Industry Ready For 'Hard Sell' To Keep Agreement Intact
Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry
PDUFA VI: A Machine To Speed R&D Time, Cut Costs
FDA Wants Better PDUFA Fees-Goals Alignment, Predictability
Spending User Fees: Biomarker Research, Drug-Device Combos?
User fees, 'Cures,' elections: FDA bracing for the crash
Are FDA pre-filing user fees in pharma's future?
PDUFA VI launches: Not Pluto flyby, but has potential
Educating Califf: Eyes opened on PDUFA, patient advocates